Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharmaBusiness Wire • 08/15/24
ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung CancerGlobeNewsWire • 08/12/24
InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor FurmonertinibBusiness Wire • 03/29/24